INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
SEC FORM 4/Option exerciseVerified dataRule 10b5-1 plan

Lin Xichen reported GPCR

CHIEF SCIENTIFIC OFFICER · Structure Therapeutics Inc. · Structure Therapeutics Inc. — Share Option (right to buy)

Side
M
Value
—
Shares
11.8K
Price
—
Executed
Aug 18, 2026
Disclosed
Aug 19, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Aug 18 executedAug 19, 2026 disclosed

GPCR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
0/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 9.0% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · GPCR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    2
    CB
    Coll Crespo BlasCHIEF MEDICAL OFFICER
    GPCRStructure Therapeutics Inc.
    Tax withholding · 10b5-1 plan
    		F$124K
    10.6K sh
    		Sep 18, 2026Sep 22, 2026
    traded Sep 18, 2026
    		+4dSEC FORM 4

    Evidence

    11
    CB
    Coll Crespo BlasCHIEF MEDICAL OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    4,008 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    20
    CB
    Coll Crespo BlasCHIEF MEDICAL OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$145K
    4,008 sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    CB
    Coll Crespo BlasCHIEF MEDICAL OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    12.0K sh
    		Sep 21, 2026Sep 22, 2026
    traded Sep 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$6,058
    17.8K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    5,939 sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    17.8K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M—
    17.8K sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    12
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$60K
    1,300 sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    13
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$4,783
    100 sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    16
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$214K
    4,539 sh
    		Sep 1, 2026Sep 2, 2026
    traded Sep 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    3,939 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    13
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$22K
    400 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    13
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$28K
    519 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    16
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Open-market sale · 10b5-1 plan
    		SELL$160K
    3,020 sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$4,018
    11.8K sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    0
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Derivative conversion · 10b5-1 plan
    		C—
    11.8K sh
    		Aug 18, 2026Aug 19, 2026
    traded Aug 18, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BJ
    Berrios John JosephChief Commercial Officer
    GPCRStructure Therapeutics Inc.
    Grant or award
    		A—
    140.8K sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BJ
    Berrios John JosephChief Commercial Officer
    GPCRStructure Therapeutics Inc.
    Grant or award
    		A—
    174.6K sh
    		Aug 6, 2026Aug 7, 2026
    traded Aug 6, 2026
    		+1dSEC FORM 4

    Evidence

    3
    LX
    Lin XichenCHIEF SCIENTIFIC OFFICER
    GPCRStructure Therapeutics Inc.
    Option exercise · 10b5-1 plan
    		M$8,036
    23.6K sh
    		Jun 25, 2026Jun 29, 2026
    traded Jun 25, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001962926-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 18, 2026
    Published
    Aug 19, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Lin Xichen
    Role
    CHIEF SCIENTIFIC OFFICER
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Structure Therapeutics Inc. — Share Option (right to buy)
    Ticker
    GPCR
    Shares
    11.8K
    Price per share
    $0
    Execution date (reported)
    Aug 18, 2026
    Owned after transaction
    142.9K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    1

    What this establishes

    Lin Xichen filed this Form 4 reporting a option exercise of GPCR on Aug 18, 2026. It became public on Aug 19, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    CHIEF SCIENTIFIC OFFICER
    Lin Xichencik:0001962926
    Issuer
    Structure Therapeutics Inc.cik:0001888886

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.

    Data sources
    SEC FORM 46m ago
    HOUSE PTR6m ago
    SEC 13F6m ago
    ROBINHOOD CHAIN6m ago